H
Hinge Health, Inc.
HNGECIK 0001673743NYSENon-AcceleratedEmerging GrowthServices-Computer Processing & Data PreparationDelawareFY ends Dec 31
Period
FY 2025
Revenue
$587.86M
Net Income
$-528.26M
Total Assets
$744.76M
Equity
$178.66M
Shares Out
0
Op. Cash Flow
$171.44M
Business
Hinge Health, Inc. is a publicly listed company in Computer Processing & Data Preparation, incorporated in Delaware. Common stock trades on NYSE under the ticker HNGE.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Revenue | 588 | 390 | 293 | |
| Cost of revenue | 120 | 91 | 99 | |
| Gross profit | 468 | 300 | 194 | |
| Research and development | 368 | 101 | 110 | |
| Sales and marketing | 317 | 167 | 148 | |
| General and administrative | 330 | 64 | 67 | |
| Total operating expenses | 1,015 | 332 | 325 | |
| Loss from operations | −546 | −32 | −131 | |
| Other income, net | 19 | 21 | 22 | |
| Net loss before income taxes | −527 | −11 | −109 | |
| Provision for (benefit from) income taxes | 998,000 | 677,000 | −405,000 | |
| Net loss | −528 | −12 | −108 | |
| Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment | 104 | 0 | 0 | |
| Net loss attributable to common stockholders | −424 | −12 | −108 | |
| Net income (loss) per share attributable to common stockholders, basic (in usd per share) | −7.77 | −0.88 | −8.31 | |
| Net income (loss) per share attributable to common stockholders, diluted (in usd per share) | −7.77 | −0.88 | −8.31 | |
| Weighted average shares attributable to common stockholders, basic (in shares) | 55 | 14 | 13 | |
| Weighted average shares attributable to common stockholders, diluted (in shares) | 55 | 14 | 13 | |
| Unrealized gain (loss) on marketable securities, net of taxes | −88,000 | 8,000 | 135,000 | |
| Comprehensive loss | −528 | −12 | −108 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 208 | 301 | 235 | — | |
| Short-term marketable securities | 156 | 166 | — | — | |
| Accounts receivable, net of allowance for credit losses of $6,092 and $6,470 as of December 31, 2025 and 2024, respectively | 66 | 42 | — | — | |
| Deferred commissions | 31 | 19 | — | — | |
| Inventory | 16 | 11 | — | — | |
| Prepaid expenses and other current assets | 57 | 45 | — | — | |
| Total current assets | 534 | 583 | — | — | |
| Long-term marketable securities | 113 | 0 | — | — | |
| Goodwill | 64 | 62 | — | — | |
| Intangible assets, net | 3 | 2 | — | — | |
| Property, equipment and software, net | 10 | 7 | — | — | |
| Operating lease right-of-use assets | 7 | 10 | — | — | |
| Other assets | 14 | 9 | — | — | |
| Total assets | 745 | 673 | — | — | |
| Accounts payable and accrued liabilities | 57 | 28 | — | — | |
| Operating lease liabilities | 4 | 4 | — | — | |
| Deferred revenue | 301 | 218 | — | — | |
| Total current liabilities | 362 | 249 | — | — | |
| Operating lease liabilities, noncurrent | 4 | 7 | — | — | |
| Total liabilities | 366 | 257 | — | — | |
| Commitments and contingencies (Note 6) | — | — | — | — | |
| Redeemable convertible preferred stock, $0.00001 par value; 4,330,341 shares of Series E authorized, 2,581,837 shares of Series E preferred stock issued and outstanding as of December 31, 2025, 48,190,771 shares authorized and 48,150,146 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $200,000 and $845,478 as of December 31, 2025 and 2024, respectively | 200 | 851 | 851 | 851 | |
| Common stock, value | — | 0 | — | — | |
| Additional paid-in capital | 1,230 | 88 | — | — | |
| Accumulated other comprehensive gain (loss) | −20,000 | 68,000 | — | — | |
| Accumulated deficit | −1,051 | −523 | — | — | |
| Total stockholders equity (deficit) | 179 | −435 | −424 | −318 | |
| Total liabilities, redeemable convertible preferred stock and stockholders equity (deficit) | 745 | 673 | — | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 5 | 6 | 6 | |
| Stock-based compensation | 643 | 739,000 | 2 | |
| Amortization of deferred commissions | 47 | 30 | 20 | |
| Accretion of discounts and amortization of premiums on marketable securities, net | 361,000 | 537,000 | −11 | |
| Excess and obsolete inventory charge | 0 | 2 | 10 | |
| Non-cash operating lease expense | 3 | 4 | 3 | |
| Provision for credit losses | 3 | 5 | 5 | |
| Deferred income taxes | 53,000 | −585,000 | −473,000 | |
| Other | 1,000 | 7,000 | 65,000 | |
| Accounts receivable | −27 | −1 | −23 | |
| Deferred commissions | −64 | −39 | −28 | |
| Inventory | −5 | 608,000 | 11 | |
| Prepaid expenses and other current assets | −16 | −9 | 6 | |
| Other assets | −181,000 | 377,000 | 677,000 | |
| Accounts payable and accrued liabilities | 29 | −11 | 12 | |
| Operating lease liabilities | −4 | −5 | −4 | |
| Deferred revenue | 83 | 77 | 36 | |
| Net cash provided by (used in) operating activities | 171 | 49 | −64 | |
| Purchase of property and equipment | −708,000 | −1 | −2 | |
| Capitalized internal use software | −5 | −3 | −3 | |
| Purchases of marketable securities | −472 | −325 | −453 | |
| Maturities of marketable securities | 369 | 347 | 459 | |
| Acquisition of a business | −4 | 0 | 0 | |
| Net cash (used in) provided by investing activities | −114 | 18 | 2 | |
| Proceeds from exercise of common stock options | 1 | 610,000 | 492,000 | |
| Issuance of common stock in connection with the employee stock purchase plan | 8 | 0 | 0 | |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | 256 | 0 | 0 | |
| Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | −295 | 0 | 0 | |
| Payment on Repurchase Agreement with Coatue | −50 | 0 | 0 | |
| Proceeds from repayment of non-recourse loans to employees | 5 | 0 | 0 | |
| Repurchase and retirement of common stock | −65 | 0 | 0 | |
| Cash paid on settlement of acquisition related holdback | 0 | 0 | −3 | |
| Payments for deferred offering costs | −10 | −3 | −645,000 | |
| Net cash used in financing activities | −150 | −2 | −3 | |
| Net increase (decrease) in cash | −93 | 65 | −65 | |
| Cash paid for income taxes | 2 | 0 | 0 | |
| Property and equipment purchased and unpaid at end of year | 0 | 0 | 36,000 | |
| Stock-based compensation capitalized in internal-use software | 1 | 0 | 0 | |
| Unpaid deferred offering costs at year end | 20,000 | 210,000 | 389,000 | |
| Right-of-use assets obtained in exchange for lease obligations | 686,000 | 0 | 1 | |
| Conversion of redeemable convertible preferred stock for Coatue in connection with initial public offering | 151 | 0 | 0 | |
| Conversion of redeemable convertible preferred stock for all other in connection with initial public offering | 347 | 0 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro